HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a $105 price target.
February 22, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics maintains a Buy rating and a $105 price target from HC Wainwright & Co., indicating a positive outlook on the stock.
The reiteration of a Buy rating and a high price target by a reputable analyst suggests a strong confidence in Denali Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100